Pharmacokinetics of cefodizime following single doses of 0.5, 1.0, 2.0, and 3.0 grams administered intravenously to healthy volunteers. 1995

B Lenfant, and F Namour, and C Logeais, and D Coussediere, and O Rivault, and A Bryskier, and A Surjus
Roussel Uclaf, Romainville, France.

Cefodizime is a new expanded-spectrum cephalosporin for parenteral use which possesses a broad antibacterial spectrum and potent antibacterial activity and is stable against most beta-lactamases. The aim of this study was to assess the pharmacokinetics of cefodizime, administered intravenously, over the dose range of 0.5 to 3.0 g in healthy volunteers. Concentrations of cefodizime in the serum and urine were determined by high-performance liquid chromatography. The area under the concentration-time curve from 0 h to infinity and the amount of drug excreted in urine from 0 to 34 h increased in a linear, dose-dependent manner with increasing doses of antibiotic from 0.5 to 3.0 g. Mean concentrations of cefodizime in plasma at the end of infusion increased from 97 to 440 mg liter-1 over the dose range 0.5 to 3.0 g and displayed a slight deviation from linearity at doses in excess of 2.0 g. Total plasma clearance (3.11 liters h-1), volume of distribution at steady state (10.5 liters), terminal elimination half-life (3.3 h), and renal clearance (1.91 liters h-1) remained constant over the doses administered. Cefodizime was well tolerated in this study.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D002439 Cefotaxime Semisynthetic broad-spectrum cephalosporin. Benaxima,Biosint,Cefotaxim,Cefotaxime Sodium,Cefradil,Cephotaxim,Claforan,Fotexina,HR-756,Kendrick,Klaforan,Primafen,Ru-24756,Taporin,HR 756,HR756,Ru 24756,Ru24756,Sodium, Cefotaxime
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013056 Spectrophotometry, Ultraviolet Determination of the spectra of ultraviolet absorption by specific molecules in gases or liquids, for example Cl2, SO2, NO2, CS2, ozone, mercury vapor, and various unsaturated compounds. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Ultraviolet Spectrophotometry

Related Publications

B Lenfant, and F Namour, and C Logeais, and D Coussediere, and O Rivault, and A Bryskier, and A Surjus
November 1990, The Journal of antimicrobial chemotherapy,
B Lenfant, and F Namour, and C Logeais, and D Coussediere, and O Rivault, and A Bryskier, and A Surjus
March 2010, Clinical and experimental pharmacology & physiology,
B Lenfant, and F Namour, and C Logeais, and D Coussediere, and O Rivault, and A Bryskier, and A Surjus
January 1986, Haemostasis,
B Lenfant, and F Namour, and C Logeais, and D Coussediere, and O Rivault, and A Bryskier, and A Surjus
February 2019, Clinical pharmacology in drug development,
B Lenfant, and F Namour, and C Logeais, and D Coussediere, and O Rivault, and A Bryskier, and A Surjus
November 1990, American journal of veterinary research,
B Lenfant, and F Namour, and C Logeais, and D Coussediere, and O Rivault, and A Bryskier, and A Surjus
November 1983, Antimicrobial agents and chemotherapy,
B Lenfant, and F Namour, and C Logeais, and D Coussediere, and O Rivault, and A Bryskier, and A Surjus
March 2017, Journal of clinical pharmacology,
B Lenfant, and F Namour, and C Logeais, and D Coussediere, and O Rivault, and A Bryskier, and A Surjus
June 2015, Journal of ethnopharmacology,
B Lenfant, and F Namour, and C Logeais, and D Coussediere, and O Rivault, and A Bryskier, and A Surjus
December 2011, Antimicrobial agents and chemotherapy,
B Lenfant, and F Namour, and C Logeais, and D Coussediere, and O Rivault, and A Bryskier, and A Surjus
January 1990, Drugs under experimental and clinical research,
Copied contents to your clipboard!